Krystal Biotech, Inc.

Krystal Biotech, Inc. is a commercial-stage biotechnology company specializing in the discovery, development, and commercialization of genetic medicines for rare diseases. The company is recognized for leveraging advanced gene therapy platforms to address unmet medical needs in dermatology and other therapeutic areas. Krystal Biotech’s products are aimed at treating debilitating and often life-threatening genetic skin disorders, with a particular emphasis on conditions like dystrophic epidermolysis bullosa, a rare inherited disorder for which the company has received regulatory approvals in both the United States and European Union. Distinguished by its integrated approach, Krystal Biotech oversees the full spectrum of drug development, from research through to market launch. The company has demonstrated robust revenue growth and increasing market capitalization in recent years, underlining its expanding footprint within the biotechnology and medical research sector. Through innovative therapies and a focus on genetic disease solutions, Krystal Biotech plays an important role in advancing treatment options for patients with rare genetic conditions, further contributing to the evolving landscape of gene-based medicines.